Related Experiment Videos
SLV-308. Solvay.
1Hines VA Hospital, Loyola University Chicago School of Medicine, Hines, IL 60141, USA. William.Wolf@med.va.gov
Current Opinion in Investigational Drugs (London, England : 2000)
|November 19, 2003
Summary
Solvay is developing SLV-308, a novel drug targeting dopamine and serotonin pathways, for potential treatment of Parkinson's disease, panic, and depression. Clinical trials are underway to evaluate its efficacy and safety in patients.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD), panic, and depression are significant neurological and psychiatric conditions.
- Current treatments may have limitations, necessitating the development of novel therapeutic agents.
Purpose of the Study:
- To investigate the potential of SLV-308 (SME-308) as an oral treatment for Parkinson's disease, panic, and depression.
- To evaluate the pharmacological profile of SLV-308 as a partial dopamine D2 agonist, noradrenergic agonist, and serotonin 5-HT1A agonist.
Main Methods:
- SLV-308 is a compound developed by Solvay.
- The drug has entered Phase II clinical trials for Parkinson's disease.
- Phase I clinical trials are being conducted for anxiety and depression.
Main Results:
- Data on efficacy and safety from ongoing trials are not yet available in this abstract.
- The pharmacological properties suggest a potential for modulating neurotransmitter systems implicated in the target conditions.
Conclusions:
- SLV-308 shows promise as a potential multi-target therapeutic agent for neurological and psychiatric disorders.
- Further clinical investigation is required to establish its therapeutic value and safety profile.